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Bone Morphogenetic Protein-2 Adsorption
onto Poly-e-caprolactone Better Preserves Bioactivity
In Vitro and Produces More Bone In Vivo than Conjugation
Under Clinically Relevant Loading Scenarios
Janki J. Patel, MS, Colleen L. Flanagan, MSE, and Scott J. Hollister, PhD
Background: One strategy to reconstruct large bone defects is to prefabricate a vascularized flap by implanting
a biomaterial scaffold with associated biologics into the latissimus dorsi and then transplanting this construct to
the defect site after a maturation period. This strategy, similar to all clinically and regulatory feasible biologic
approaches to surgical reconstruction, requires the ability to quickly (< 1 h within an operating room) and
efficiently bind biologics to scaffolds. It also requires the ability to localize biologic delivery. In this study, we
investigated the efficacy of binding bone morphogenetic protein-2 (BMP2) to poly-e-caprolactone (PCL) using
adsorption and conjugation as a function of time.
Methods: BMP2 was adsorbed (Ads) or conjugated (Conj) to PCL scaffolds with the same three-dimensional
printed architecture while altering exposure time (0.5, 1, 5, and 16 h), temperature (4C, 23C), and BMP2
concentration (1.4, 5, 20, and 65mg/mL). The in vitro release was quantified, and C2C12 cell alkaline phosphatase
(ALP) expression was used to confirm bioactivity. Scaffolds with either 65 or 20mg/mL Ads or Conj BMP2 for 1 h
at 23C were implanted subcutaneously in mice to evaluate in vivo bone regeneration. Micro-computed tomog-
raphy, compression testing, and histology were performed to characterize bone regeneration.
Results: After 1 h exposure to 65mg/mL BMP2 at 23C, Conj and Ads resulted in 12.83– 1.78 and 10.78–
1.49mg BMP2 attached, respectively. Adsorption resulted in a positive ALP response and had a small burst
release; whereas conjugation provided a sustained release with negligible ALP production, indicating that the
conjugated BMP2 may not be bioavailable. Adsorbed 65mg/mL BMP2 solution resulted in the greatest re-
generated bone volume (15.0– 3.0mm3), elastic modulus (20.1– 3.0MPa), and %bone ingrowth in the scaffold
interior (17.2%– 5.4%) when compared with conjugation.
Conclusion: Adsorption may be optimal for the clinical application of prefabricating bone flaps due to BMP2
binding in a short exposure time, retained BMP2 bioactivity, and bone growth adhering to scaffold geometry and
into pores with healthy marrow development.
Introduction
The gold standard for reconstructing a bone defect is avascularized autologous flap. However, this procedure
results in donor site morbidity and poorly matched defect
geometry, especially for craniofacial reconstruction. Alter-
natives to autografts include allografts and synthetic grafts.
Allografts carry the risk of transferring diseases and eliciting
an immune response. Synthetic grafts made from polymers
or metal cages are alternatives being investigated to address
the drawbacks of allografts and autografts. Particularly,
polymers can be fabricated to match the patient’s complex
facial geometry and be integrated with biologics to induce
bone growth when implanted into the defect site. Although
these grafts could be readily available and produced, they do
not integrate as well as autografts into the host bone.1
Chronically infected and irradiated wound sites are chal-
lenging to reconstruct and are not conducive to general
wound healing, let alone being able to support a bone graft.
Furthermore, blood vessels generally cannot penetrate the
graft sufficiently to provide nutrients to the bone growing at
the graft’s core, especially in large-volume defects. To in-
crease viability and integration of grafts implanted directly
into the defect site, researchers are investigating prefabri-
cation of a synthetic flap that is assembled at a site remote
from the defect.2–5 As an alternative to creating the flap
in vitro (in which patient cells are harvested, expanded, and
seeded on the construct to mature in an external bioreactor),
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we are looking to tissue engineer a bone flap in vivo by
using the patient’s body as a bioreactor to achieve bone
penetration into a biomaterial scaffold with associated bio-
logics. There are a few reports of this procedure in animal
models4,6–10 and even less in humans.2,3,11 Previous studies
have used BioOss/Hydroxyapatite blocks or titanium trays
filled with BioOss blocks soaked in growth factors (GF).7,8
A human mandibular case using a titanium mesh filled with
hydroxyapatite blocks soaked in bone morphogenetic pro-
tein-7 (BMP7) fractured and failed.2
Our goal is to advance this prefabricated flap procedure
by integrating patient-specific computational design, three-
dimensional (3D) biomaterial printing, and postfabrication
biologic functionalization.12 Poly-e-caprolactone (PCL) is a
biocompatible and bioresorbable polymer that can be uti-
lized with image-based computation-aided design and se-
lective laser sintering (SLS) manufacturing techniques.13
SLS can repeatedly and reproducibly produce PCL scaffolds
with complex geometries, controlled pore size, and stiffness
that degrade over 3 years. Its degradation profile and me-
chanical properties support its use for bone tissue engi-
neering in complex reconstruction sites where bone may
take over a year to form. In these sites, a PCL scaffold’s
slower degradation time is an advantage to provide form and
load bearing over a longer time period. Furthermore, PCL
degradation generates less acidic byproducts and leads to
less inflammation than more rapidly degrading polylactic
acid-based co-polymers.14 PCL has been approved for cra-
nioplasty bone-filling applications by the FDA.15,16 Thus,
the polymer has been widely tested, utilized, and achieved
regulatory approval as a bone repair scaffold. Furthermore,
it may readily be formed into complex geometries by 3D
printing techniques such as SLS and Fused Deposition
Modeling.17–20
PCL can be modified to integrate the osteoinductive
agent recombinant human bone morphogenetic protein-2
(BMP2).21,22 However, further studies are needed to refine a
method of GF functionalization onto PCL scaffolds to pro-
duce bone when placed in the muscle bed (i.e., prefabricated
flap applications) in a clinically realistic time frame within
the operating room (OR). Although a plethora of methods
have been developed for conjugating and delivering BMP2
from scaffold materials, any conjugation technique requiring
more than 1 h and performed outside the OR faces unknown
sterilization effects on GF bioactivity and creates a signifi-
cant uphill battle to be of any clinical relevance. It is likely
that any clinically relevant BMP2 delivery method for the
near future should be performed in the OR environment at
room temperature with loading times of 1 h or less. Current
conjugation methods that more efficiently load BMP2 onto
scaffolds than adsorption methods23,24 do not fulfill these
requirements. In addition, studies that have assessed con-
jugation methods utilized either porogen leaching22,23 or
other methods, resulting in large variations in pore archi-
tecture that may significantly affect release kinetics, not
allowing a rigorous comparison of adsorption and conju-
gation methods.25–27 Simpler adsorption methods have not
been directly compared with conjugation methods.27–29
Still, there is a lack of information on how conjugation
methods could be compared directly with adsorption
methods under OR relevant conditions on scaffolds with the
exact same, rigorously controlled architecture in terms of
not only in vitro loading efficiency and bioactivity but also
the direct translation into in vivo bone formation in terms of
volume, localization, and mechanical properties. The goal of
this study was to investigate these questions both in vitro
and in an in vivo ectopic model as a precursor to large
animal ectopic models for prefabricated flap construction.
Materials and Methods
PCL fabrication
PCL discs (15mm diameter, 2mm height, and 176mm2
surface area) and 70% porous scaffolds (6.35mm diameter
· 4mm height, 170mm2 surface area) with 2.15mm spheri-
cal pores (Fig. 1) in a 2mm unit cell were fabricated using
a Formiga P100 SLS machine (EOS, Inc.). The powder
consisted of PCL (43–50 kDa; Polysciences) and 4wt%
hydroxyapatite (Plasma Biotal Limited). Manufacturing
conditions, including bed temperature, laser power, particle
size, and PCL milling, followed protocols that had been
previously developed and published for implantable PCL
scaffolds.13,17,30,31 After manufacturing, the discs and scaf-
folds were air blasted and then sonicated in 70% ethanol
(EtOH) for 30min to remove nonsintered powder, washed in
distilled water (diH2O), and air dried at room temperature.
BMP2 binding
For conjugation groups (Conj), PCL samples were ex-
posed to 10% w/v 1,6-hexanediamine in isopropanol for 1 h
at 37C to add amine groups via aminolysis and then they
were washed in diH2O. After air drying overnight, 1M
Ninhydrin reagent (Sigma), prepared with 100% EtOH, was
used to confirm successful aminolysis in a representative
specimen by development of a purple stain. Note that this
preparation can be done presterilization and does not affect
the capability to perform conjugation under OR relevant
conditions. The samples were prewashed with activation
buffer (BuPH Phosphate-Buffered Saline Pack in diH2O, pH
7.2 Pierce Biotechnology). The heterobifunctional cross-
linker sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-
1-carboxylate (sulfo-SMCC; Pierce Biotechnology) was
used to immobilize recombinant human BMP2 (Escherichia
coli derived; Creative Biomart) on the aminated surface.
Samples were immersed in sulfo-SMCC (4mg/mL in acti-
vation buffer) for 1 h at 23C, followed by activation and
conjugation buffer washes. Conjugation buffer (pH 7.0)
contained activation buffer and 0.1M EDTA. Adsorption
FIG. 1. (A) PCL scaffold (B) PCL disc. PCL, poly-e-
caprolactone.
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groups (Ads) followed the same procedure as Conj but
without the aminolysis and sulfo-SMCC reactions. E. coli-
derived BMP2 is nonglycosylated and has been shown to
produce more bone in vivo at a lower dose when compared
with a glycosylated BMP2.32 BMP2 was dissolved in
20mM acetic acid (1mg/mL) and then further diluted in
conjugation buffer to the desired concentration. Ads/Conj
PCL discs (n = 3/group) were immersed in 1mL of 1.43 mg/
mL BMP2 solution for 0.5, 1, 5, or 16 h on a shaker at 4C
or 23C. A simple disc geometry was used to understand
initial binding trends before conducting concentration
binding studies with a refined protocol on a more complex
geometry. Ads/Conj PCL scaffolds (n = 3/group) were im-
mersed in 1mL of 1.4, 5, 20, or 65 mg/mL BMP2 for the
refined conditions of 1 h exposure at 23C. Note that an
enzyme-linked immunoabsorbant assay (ELISA) was used
to determine the detected BMP2 concentration (averaging
1.14, 3, 6.5, and 30mg/mL) with which to normalize binding
values. Once BMP2 exposure was complete, samples were
washed with diH2O and dried in a vacuum at 23C over-
night. BMP2 solution supernatants and diH2O washes were
collected in LoBind microcentrifuge tubes (Eppendorf) to
analyze for BMP2 content. Bovine serum albumin (BSA)
1% was added to the collected solution to result in 0.1%
BSA, and the samples were stored at - 80C. BMP2 content
was quantified using an indirect ELISA kit (PeproTech)
read at 405 and 650 nm on a microplate reader (Multiskan
Spectrum; Thermo Scientific). Results are reported as
BMP2 bound (mg), BMP2 bound per mm2 PCL surface area
(mg/mm2), or binding efficiency (%) and were calculated as
shown next:
BMP2 Bound (lg)¼BMP2 in original solution
detected by ELISA
 (BMP2 in supernatantþwashes)
Binding Efficiency (%)
¼ original AmtAmt remaining in sol¢n
original Amt
 
 100
Release kinetics
Ads and Conj BMP2 release profiles were determined for
PCL scaffolds exposed to 20 mg/mL BMP2 for 1 h at 23C
(n = 3). After BMP2 exposure, PCL samples were immersed
in Dulbecco’s phosphate-buffered saline (DPBS) and incu-
bated in a sterile environment at 37C, 5% CO2, and 95%
humidity. The supernatant was collected and replaced
with fresh DPBS at 1, 3, 5, 7, 14, and 21 days after initial
exposure. Supernatant with added 0.1% BSA was stored at
- 80C until BMP2 quantification by ELISA.
BMP2 quantification
An E. coli-derived BMP2 ELISA quantification kit (Pe-
protech) was used to indirectly quantify the amount of
BMP2 bound to PCL and was conducted according to the
manufacturer’s instructions. High-binding 96-well plates
(Costar) were coated with capture antibody overnight. Wells
were blocked with 1% BSA in DPBS for 1 h; thawed sam-
ples were added in triplicate wells for 2 h, detection anti-
body for 2 h, and Avidin-conjugated horseradish peroxidase
for 0.5 h, followed by the addition of ABTS liquid substrate
solution (2,2¢-azino-bis(3-ethylbenzthiazoline)-sulfonic acid;
Sigma) for colorimetric reading after 20min. In between
each step, wells were washed four times with wash buffer
(DPBS containing 0.05% Tween 20; Sigma). Absorbance
was read at 405 and 650 nm.
Cell culture
C2C12 myoblastic cells are known to differentiate down
an osteogenic lineage when exposed to active BMP2 and are
extensively used in other studies as an initial screening of
BMP2 bioactivity.33–36 C2C12 cells (ATCC) were grown in
high-glucose Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum and 1% penicillin/
streptomycin and incubated at 37C, 5% CO2, and 95%
humidity (all reagents from Gibco). The Ads and Conj
BMP2 discs were sterilized in 0.22 mm-filtered 70% EtOH
for 30min, washed with Hanks balanced salt solution
(HBSS), and maintained in DMEM under sterile conditions
until cell seeding in a 24-well plate. Discs fit tightly into the
well space. The DMEM was then replaced with culture
medium, and cells were added.
Alkaline phosphatase assay
C2C12 cells were seeded (1· 104 cells/disc or 57 cells/
mm2) on discs with conjugated or adsorbed 0.7mL of
1.4 mg/mL BMP2 for 1 h at 23C. Simple disc geometry was
used for cell studies, because the aim of the study was to
determine whether the bound BMP2 maintained bioactivity
and the extent of bioactivity was not compared. Positive
controls were 1 mg BMP2 in culture medium (sol BMP2)
and 0.7mL of 1.4 mg/mL BMP2 adsorbed for 16 h at 4C
due to earlier successful results in this laboratory for in vivo
formation at that binding condition (n = 4). The negative
controls were cells on PCL discs with no BMP2. After 4
days of static culture, cells were lysed with 700 mL of Cel-
Lytic (Sigma) solution and alkaline phosphatase (ALP)
production was quantified. The assay was conducted using
alkaline buffer solution, p-nitrophenol standard solution,
and ALP substrate tablets (Sigma). Each sample (n = 3/
group) was read in triplicate wells at 405 nm, and results
were normalized to total intracellular protein content (BCA
ThermoScientific) read at 562 nm.
MTS assay
An MTS assay was utilized to ensure cells attached and
grew on the PCL to interact with the bound BMP2. Pro-
liferation between groups was not compared. C2C12 cells
were seeded (2.5 · 104 cells/disc) on discs with Conj or Ads
1.43 mg/mL BMP2 for 1 h at 23C and Ads at 4C (n= 4).
The positive controls were cells seeded on PCL discs ex-
posed to 1 mg BMP2 in culture medium (sol BMP2). The
negative controls were cells on PCL discs with no BMP2.
Two hundred sixty microliters of MTS solution (CellTiter96
Aqueous One Solution; Promega) were added to each disc
after 72 h of static culture. After incubation for 2 h at 37C,
triplicates were read at 490 nm.
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In vivo bioactivity: subcutaneous implantation
Based on our in vitro studies, we chose the most clinically
relevant conditions of 1 h protein exposure at 23C and
exposed scaffolds to 20 or 65mg/mL adsorbed or conjugated
BMP2. After treatment, scaffolds were implanted subcuta-
neously in 5–7 week-old NIHS bg-nu-xid mice (Harlan
Laboratories). Negative controls for the adsorption group
were PCL scaffolds soaked in conjugation buffer for 1 h.
Negative controls for the conjugation group were PCL
scaffolds treated through the sulfo-SMCC reaction step
without BMP2 exposure. Groups were sterilized with 70%
EtOH and washed with HBSS before implantation. Four
scaffolds were implanted in each mouse. An incision was
made in the back, and four pockets were created angling
toward each limb. Scaffolds were assigned a quadrant to be
implanted in such that at least one sample from each group
was implanted in all quadrants. Mice were then euthanized
at 8 weeks postsurgery to explant the specimen. Explanted
specimens were placed in Z-Fix (Anatech) overnight,
washed with diH2O for 5 h, and stored in 70% EtOH until
testing. Table 1 gives total sample numbers as well as the
number of samples used for each specific assay (microCT
scan, mechanical test, and histology). This study was con-
ducted in compliance with the regulations set forth by the
University Committee on Use and Care of Animals at the
University of Michigan.
Micro-computed tomography
Fixed scaffolds were scanned in water with a high-
resolution micro-computed tomography (microCT) scanner
(Scanco Medical) at 16 mm resolution, and scans were ca-
librated to Hounsfield units (HU). Bone volume (BV), tissue
mineral density (TMD), and tissue mineral content (TMC)
data were determined. Bone was defined at a threshold of
HU = 1050 using Microview software (Parallax Innova-
tions). TMD is an assessment of bone quality within the
scaffold; the measure indicates the average density of the
bone tissue (as defined by the threshold value of 1050 HU)
within a given 3D region of interest (ROI) and is reported as
the mass of hydroxyapatite per volume (mgHA/mm3). TMC
quantifies the amount of mineral present in the bone (as
defined by the threshold value of 1050 HU) in a given ROI
and is reported as the mass of hydroxyapatite (mgHA). To
obtain TMD and TMC values, Dicoms from Scanco were
imported into Microview and grayscale values for each
voxel were exported to excel and be converted to HU val-
ues. The scaffold region was represented as a cylindrical
ROI (6· 3.615mm). Bone formed outside the scaffold ROI
boundary was quantified and defined as ‘‘external’’ bone
growth, and bone inside the scaffold ROI was defined as
‘‘internal’’ BV. External, internal, and total BV, TMD, and
TMC were calculated for each specimen.
To determine bone penetration into the scaffold radially,
four concentric, cylindrical rings were defined as ROIs and
were individually analyzed with regard to BV and TMC.
The diameters of the four concentric rings are as follows:
Ring 1: 6.00–4.84mm, Ring 2: 4.84–3.67mm, Ring 3: 3.67–
2.5mm, and Ring 4: 2.50–0.00mm. BV, and bone ingrowth
of each ring were calculated using Microview Software.
Bone ingrowth (%) was calculated as BV divided by the
available pore volume for each ring. Available pore volume
was calculated from the porosity of each ring based on the
.STL design file for the scaffold.
Compression mechanical testing
Specimens were mechanically tested using an MTS Alli-
ance RT30 electromechanical test frame (MTS Systems
Corp.) with a 500N load cell. Samples were compressed be-
tween two steel platens at a rate of 1.0mm/min with a 0.5 lbf
preload. Data were collected and analyzed using TestWorks4
software (MTS Systems, Corp.). Data were collected to a 25%
strain, and the compressive elastic modulus was defined as the
slope of linear region of the stress-strain curve before the 15%
strain. Data were normalized to scaffold area.
Histology
Fixed samples from each group were decalcified with
RDO (Sigma) and sent to the Histology Core at the Uni-
versity of Michigan Dental School to be embedded in par-
affin, sectioned, and stained with hematoxylin and eosin
(H&E). H&E was used to visualize cells, tissue matrix,
blood vessels, and general tissue morphology. A light mi-
croscope was used to image sections at 10·magnification.
Statistical analysis
Data are expressed as mean – standard deviation of the
mean. An analysis of variance was used to determine sta-
tistical significance between groups. A *p-value < 0.05 (a
< 0.05) was considered statistically significant on a 95%
confidence interval.
Results
Binding environment studies
At 4C, conjugation had significantly more BMP2 at-
tached than adsorption at all exposure times. At 23C,
conjugation still had significantly higher binding at 0.5 and
1 h exposures. Adsorption at 23C resulted in significantly
more BMP2 bound than at 4C except at the 16 h exposure.
After 1 h exposure at 23C, conjugated and adsorbed discs
resulted in 0.0049– 0.001 mg/mm2 (99.5%– 0.1%) and
0.0036 – 0.0001mg/mm2 (73.3% – 1.3%) BMP2 attached,
respectively (Fig. 2). Based on these results, we examined
Conj/Ads groups that were exposed to BMP2 for 1 h at 23C
in further studies.
Table 1. Sample Numbers for In Vivo Analysis
Number of Samples Used in Explanted
Specimen Analysis Methods
Group
microCT
scan
Mechanical
test Histology
Total
samples
20 mg/mL Conj n = 8 n = 5 n = 3 n = 8
65 mg/mL Conj n = 9 n = 6 n = 3 n = 9
20 mg/mL Ads n = 8 n = 5 n = 3 n = 8
65 mg/mL Ads n = 9 n = 6 n = 3 n = 9
PCL-no BMP2 n = 5 n = 3 n = 2 n = 5
Sulfo-SMCC n = 9 n = 6 n = 3 n = 9
Ads, adsorption; BMP2, bone morphogenetic protein-2; Conj, conjunc-
tion; microCT, micro-computed tomography; PCL, poly-e-caprolactone.
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BMP2 in vitro bioactivity
To determine whether the bound BMP2 was nontoxic and
bioactive, we seeded C2C12 myoblastic cells on BMP2 Ads
or Conj PCL discs. We found that cells on all PCL discs
proliferated significantly more than the negative control
(Fig. 3A). Cells on adsorbed groups produced significantly
higher ALP than the conjugated group. ALP production of
cells on PCL without BMP2 was the same as conjugation
and significantly less than adsorption. There was no differ-
ence between discs that had BMP2 adsorbed at 4C or those
at 23C ( p = 0.10). Finally, the positive control of soluble
BMP2 in cell culture medium showed significantly higher
ALP (1.16 nM ALP/mg protein/min) compared when with
all other groups (Fig. 3B).
Concentration binding studies
For a transition to in vivo bioactivity studies, 70% porous
scaffolds (176mm2) were exposed to increasing BMP2 con-
centrations for 1 h at 23C (adsorbed and conjugated). The
BMP2 bound to scaffolds was compared with the amount
adsorbed onto a disc (170mm2). There was no significant
difference in binding between adsorbed/conjugated scaffolds
and discs at 5, 20, and 65mg/mL. Significantly more BMP2
bound to the surface as BMP2 concentration increased (Fig.
4A). When exposed to 20mg/mL BMP2, 3.03– 0.18mg
(0.018– 0.001mg/mm2) BMP2 attached with conjugation and
2.49– 0.35mg (0.015– 0.002mg/mm2) attached with adsorp-
tion. When exposed to 65mg/mL, conjugation and adsorption
bound 12.83– 1.78mg (0.076– 0.01mg/mm2) and 10.78–
1.49mg (0.063– 0.01mg/mm2) BMP2, respectively. Figure
4B shows the percentage of BMP2 in the original solution
that bound to the scaffold surface (% binding efficiency).
Conjugation bound significantly more BMP2 than adsorption
when exposed to 1.4mg/mL. There was no difference in
amount bound between the two methods as BMP2 concen-
trations increased to 5, 20, and 65mg/mL.
In vitro release kinetics
A carrier device’s release kinetics plays a crucial role in
the quality of engineered bone. PCL scaffolds exposed to
20mg/mL BMP2 solution for 1 h at 23C showed that after
22 days, 0.0026 – 0.0006 and 0.0167– 0.005 mg of conju-
gated and adsorbed BMP2 was released, respectively (Fig.
5A). A burst release commonly observed with adsorption
occurred in the first 1–3 days, during which about 0.0068 mg
BMP2 was released (Fig. 5B).
In vivo bone formation
After 8 weeks of subcutaneous implantation, we found
that adsorbed PCL scaffolds exposed to 20 and 65mg/mL
BMP2 solution produced the greatest total BV of 9.2 – 2.28
and 15.02– 2.98mm3, respectively. Conjugation produced
0.43 – 0.41 and 5.9 – 2.0mm3 total bone when exposed to 20
or 65mg/mL, respectively. Negative control blank PCL
produced significantly less bone (0.14 – 0.03mm3) than all
other groups (Fig. 6A). Using Microview to visualize mi-
croCT scans of explanted specimen, we found that conju-
gation produced a shell of bone that followed scaffold
geometry. Adsorption resulted in bone following scaffold
geometry as well as filling into the pores (Fig. 6B). The bone
formed outside of the scaffold ROI for 65mg/mL adsorp-
tion (1.42 – 0.52mm3) and 65 mg/mL conjugation (0.14–
0.08mm3) was not excessive (Fig. 6A, B).
Sixty-five mg/mL adsorbed also had significantly higher
TMC (8.44 – 1.7mg HA) than other groups. Finally, 65 mg/
mL conjugated, 20mg/mL adsorbed, and 65 mg/mL adsorbed
produced bone that is within the normal density range of
FIG. 2. BMP2 binding to PCL discs via adsorption or
conjugation. PCL discs were exposed to 1.4mg/mL BMP2
solution for 0.5, 1, 5, or 16h at 23C or 4C. BMP2 was
quantified with an ELISA (n= 3). BMP2, bone morphogenetic
protein-2; ELISA, enzyme-linked immunoabsorbant assay.
Color images available online at www.liebertpub.com/tec
FIG. 3. BMP2/PCL cytotoxicity and bioactivity. (A) MTS assay results for relative C2C12 proliferation on BMP2/PCL
discs. Cells were able to grow on PCL surface modified with BMP2 (n = 4). (B) ALP production of C2C12 cells seeded on
BMP2/PCL discs. Data are normalized to total intracellular protein content and based on linear curve fit. *p < 0.05 was
significant. ALP, alkaline phosphatase.
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mandibular bone (551– 25, 587 – 25, and 560 – 37mg HA/
cm3, respectively).13,37
Ring analysis showed a similar relationship in that ad-
sorption resulted in higher %bone ingrowth in all rings when
compared with conjugation. Percent bone ingrowth was the
same throughout the scaffold for 65 mg/mL adsorption. At
the center of the scaffold, 65 mg/mL adsorption and conju-
gation had 17.2% – 5.4% and 7.5% – 3.07% ingrowth, re-
spectively (Fig. 7).
Mechanical testing
As seen in Figure 8, nearly all groups had significantly
higher moduli when compared with the blank PCL (12.7–
1.1MPa) or sulfo-SMCC negative controls, with the ex-
ception of 20 mg/mL conjugated ( p = 0.12). The 65 mg/mL
adsorbed group had the highest elastic modulus of 20.1–
3.0MPa, which was significantly higher than the 65 mg/mL
conjugated group (15.1– 1.3MPa). However, at a lower
concentration level, there was no difference between 20 mg/
mL conjugated and 20 mg/mL adsorbed moduli.
Histology
Scaffold pores of sulfo-SMCC, blank PCL, and 20 mg/mL
conjugated BMP2 were infiltrated primarily with fibrous and
fatty tissue (Fig. 9). Negligible bone formation was ob-
served in these groups. However, both of the adsorbed
groups (20 and 65mg/mL) showed blood, bone, and fatty
marrow growth into the scaffold pore space. There were
multiple osteocytes embedded in the osteoid as well as os-
teoblasts lining the matrix. The 65 mg/mL conjugated group
showed bone growth, fibrous tissue, and a little fatty marrow
as well; however, the resulting bone was primarily localized
to the pore surface and did not grow into the pores as well as
the adsorbed group.
Discussion
Prefabricating a bone flap in vivo has been completed in
Europe and Asia, but to the best of our knowledge, it has not
yet been completed in the United States. For the foreseeable
future, this will likely be the method that can best generate
large vascularized bone constructs for reconstruction.
Medtronic’s product Infuse has been FDA approved for
delivery of BMP2 from a collagen type 1 sponge in treat-
ment of spinal fusion, open tibial fractures, sinus augmen-
tation, and dental procedures.38 Due to BMP2’s short half-
life, a 1.5mg/mL BMP2 dose was needed (greatly exceed-
ing native concentrations of 18.8–22 pg/mL), which resulted
in a large burst release during the first 2–3 days, causing
adverse reactions in some patients.39 To control the release
and prevent excessive bone growth, Park et al. chemically
conjugated BMP2 to amine-containing chitosan with a
FIG. 4. BMP2 binding to PCL discs and scaffolds. (A) PCL scaffolds were exposed to 1.43, 5, 20, or 65 mg/mL BMP2
solution for 1 h at 23C. The data were normalized to the ELISA detected concentration, which averaged at 1.14, 3, 6.5, and
30 mg/mL. *p < 0.05. (B) Bound BMP2 is expressed as a percentage of BMP2 in original solution (n= 3). Color images
available online at www.liebertpub.com/tec
FIG. 5. Conjugated and adsorbed BMP2 released from PCL. (A) Cumulative release of BMP2 from PCL scaffolds into
DPBS when exposed to 20 mg/mL BMP2 for 1 h at 23C. Release environment conditions were sterile, 37C, 5% CO2, and
95% humidity. *p < 0.05. (B) BMP2 (mg) released per day. The supernatant was analyzed for BMP2 content with an ELISA
(n = 3). DPBS, Dulbecco’s phosphate-buffered saline. Color images available online at www.liebertpub.com/tec
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sulfo-SMCC cross-linker. Conjugation enhanced in vitro
osteoinductive properties as determined by preosteoblast
differentiation; however, chitosan would not be an ideal
carrier for creating a bone flap, because it lacks mechanical
integrity.25 BMP2 adsorption and conjugation via heparin
and sulfo-SMCC onto uncoated polymer surfaces (PLGA
and PCL) has been superficially compared, but a study was
needed to refine a simple BMP2-binding method onto 3D
SLS manufactured PCL scaffolds in a clinically applicable
environment.22,23
In this study, we aimed at refining a protocol for binding
BMP2 to PCL, considering the constraints of intra OR use
and for testing bone regeneration using the sulfo-SMCC and
simple adsorption binding protocols in vivo. Studies have
used various methods to deliver BMP2 from biomaterials,
including sulfo-SMCC, heparin, trauts, adsorption, and in-
corporation into a coating or microparticles.24,26,29,36,40–44
Temperatures and exposure times at which protein binding
studies have been tested range from 4C to 37C and from
1 h to 24 h.25,36,45,46 However, temperatures outside room
temperature and long exposure times make it very difficult
to use such BMP2 conjugation methods clinically. In this
study, we found that chemical conjugation with sulfo-
SMCC bound more BMP2 during a shorter exposure time
and at ambient temperature in comparison to adsorption;
however, the conjugated BMP2 did not maintain bioactivity
once bound to the surface as determined by an absence of
ALP production in vitro. This inactivity could be due to the
sulfo-SMCC binding reaction binding BMP2 in a confor-
mation that does not ideally present its cell-binding moiety.
FIG. 6. Regenerated Bone
Analysis. (A)Microview Soft-
ware analysis for bone volume
formed in explanted specimen
using microCT scans (thresh-
old=1050 HU). ‘‘Inside scaf-
fold’’ was defined as bone
volume inside a cylindrical
ROI (6mm D, 3.615mm H),
and ‘‘outside scaffold’’ was the
bone volume formed outside
the ROI. (B)Microview
Software Visual Analysis of
microCT Scans. Two repre-
sentative samples from each
group are shown. Bright white
areas indicate bone formation
(blue arrow), and gray areas
are scaffold (red*). Dark areas
(orange dashed lines) indicate
pores. Conjugation produced
bone that closely followed PCL
surface geometry. Adsorption
produced bone growth into the
pores in addition to following
surface geometry. *p<0.05.
HU,Hounsfieldunits;microCT,
micro-computed tomography;
ROI, region of interest. Color
images available online at
www.liebertpub.com/tec
FIG. 7. RingAnalysis for BoneGrowth into Scaffold. (A)Outer ROI diameterswere 6.0, 4.84, 3.67, and 2.50mm forRings 1, 2,
3, and 4, respectively. (B) Percentage bone ingrowth (bone volume divided by available pore space) showed that 65mg/mL
adsorbed group had significantly more ingrowth than either of the conjugated groups. (C) Sixty-five mg/mL adsorbed group
resulted in the same bone penetration throughout the scaffold. *p< 0.05. Color images available online at www.liebertpub.com/tec
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Even though adsorbed BMP2 may not have bound as effi-
ciently as conjugated BMP2 at 23C, it was shown to be
bioactive in vitro and produced more bone that infiltrated
the scaffold and pores in vivo. We also showed that ad-
sorbed BMP2 bound more efficiently at 23C than at 4C,
which is a clear advantage for the intra OR setting. This
increased binding may have been due to increased protein
kinetics providing the protein with more opportunities to
bind to the material surface.
GF delivery vehicle release kinetics are crucial to the
resulting bone formed. Conjugation resulted in sustained GF
release, whereas adsorption had a slightly higher burst re-
lease after 1–3 days, followed by a sustained release over
time. This burst release with adsorption is commonly seen in
other studies26,27,36; however, in this case when BMP2 is
delivered from laser sintered PCL, the amount released, in a
burst and during subsequent slower release, at the secondary
site is extremely small ( < 1%), which is much smaller than
the other studies.26,36,46 The released amount is still thera-
peutically relevant, because the regenerated bone increased
the scaffold’s load-bearing abilities. Since the in vitro re-
lease was at 37C, the remaining BMP2 could have de-
graded and the ELISA may not have detected the BMP2
fragments. Although an ELISA is a widely used method to
detect low BMP2 concentrations, an alternate detection
method that could be utilized to confirm the release kinetics
would be to use 125I-labeled BMP2.25 Overall, adsorption
provided greater BMP2 release over time. A limitation to
this study was that the in vitro release profile may not en-
tirely accurately predict the in vivo release profile due to
physiological factors such as enzymes cleaving BMP2 off
the surface.
For a transition to in vivo studies and to confirm BMP2
bioactivity, we increased the amount of BMP2 exposed to
PCL and used a more complex geometry. We determined
the same amount of BMP2 adsorbed onto discs as onto
scaffolds and that samples bound increasingly more mg
BMP2/mm2 when they were exposed to increasing BMP2
concentrations. The higher concentrations may have caused
a stronger concentration gradient which drove adsorption at
a rate similar to that of conjugation. The in vivo study
showed that adsorption on PCL may be more clinically
applicable, because not only did bone formation follow
scaffold surface geometry similar to conjugation but it also
grew into the interior available pore space. This increased
bone ingrowth is likely the reason that adsorption had a
higher elastic modulus than conjugation groups. This su-
perior mechanical integrity will be crucial once the bone
flap is transferred to the defect site. Adsorption also pro-
vided the most overall bone growth as well as bone formed
at the center of the scaffold. When applied to a bone flap
model, it is important to produce as much bone as possible
before transferring it to assist the flap to integrate into the
defect site as well as to facilitate further bone remodeling
and growth. The ectopic model for bone regeneration was,
due to our interest in prefabricated flaps, the process by
which we wanted to test BMP2 delivery.
This scaffold was acellular when implanted; therefore, we
speculate that circulating cells such as mesenchymal stem
cells and fibroblasts which migrated through the vasculature
in the wound bed could have interacted with the released
BMP2 and were involved in endochondral bone formation.
Due to a lack of bioactivity exhibited in vitro, but the pres-
ence of bone formed in vivo, we believe that conjugated
BMP2 may be released via proteolytic activity and adsorption
may release the protein through weak molecular interactions.
FIG. 8. Compressive mechanical testing. Specimen elastic
modulus measured in compression was defined as the slope
of linear region before 15% strain level and normalized to
specimen surface area. *p < 0.05.
FIG. 9. Hematoxylin and
eosin images of PCL/BMP2
scaffold pores. Bright-field
images of scaffold pores
taken at 10· magnification.
b, bone; f, fibrous tissue;
m, marrow; s, scaffold.
Negative controls consisted
mainly of fibrous tissue.
Color images available
online at www.liebertpub
.com/tec
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Overall, adsorption onto PCL makes BMP2 available faster to
cells than conjugation via sulfo-SMCC. In the future, we
would like to determine a dual GF delivery system to increase
the bone growth rate into the scaffold so that the flap can be
transplanted at an earlier time point for oncology patients
waiting for adjunct therapy.
Conclusions
To address the drawbacks associated with autographs,
allografts, and synthetic grafts, we propose the idea of
prefabricating a flap that is autologous in nature. The ability
to create complex PCL geometries for craniofacial recon-
struction is an advance in prefabricating flaps, as only crude
geometries were utilized in other cases. Based on these
studies, adsorbing BMP2 onto PCL may be more optimal for
clinical use in comparison to conjugation via sulfo-SMCC
due to BMP2 binding in a short exposure time at ambient
temperature, retained BMP2 bioactivity, bone growth fol-
lowing scaffold geometry and into pores, and healthy mar-
row development. Further studies are currently being
conducted to determine whether these in vivo results can be
replicated in a large porcine model and, furthermore,
transplant the PCL implant to a mandibular angle defect. We
will compare the prefabricated flap results to a PCL implant
placed directly into the defect site.
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